TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time to Development of Tuberculosis Disease or Death
Endpoint domain: Mortality/survival
Primary endpoint: Time to Development of TB Infection or Death
Endpoint domain: Mortality/survival
Primary endpoint: Number of youth screened for trauma exposure and PTSD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of youth starting TF-CBT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of youth completing TF-CBT in each condition
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 6-Minute walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Insulin Lispro Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Observed Insulin Lispro Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjects' satisfaction after treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of subjects diagnosed with gastric diffuse lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of gastric focal lesions founded
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: time to fatal or non-fatal cardiovascular event
Endpoint domain: Mortality/survival
Primary endpoint: toxicity of adding chloroquine
Endpoint domain: Adverse events/effects
Primary endpoint: Increased levels of PTSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased levels of suicidality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased levels of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum (peak) plasma drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum (peak) plasma concentration following drug administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of MgSo4 treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resuscitation volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Able to Taper Steroid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival Estimate of Time to Flare
Endpoint domain: Mortality/survival
Primary endpoint: Number of IV-Insulin Therapy sessions until stabilization of Blood Glucose level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in mindfulness score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Radiological Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in monoamine oxidase (MAO-B) enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily Symptom Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lactates on peripheral venous and arterial blood gases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Anti-Müllerian Hormone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Rates of grade 3 or higher toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in urinary albumin-creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in hand strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in The PROMIS-29
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in PROMIS upper extremity tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attained linear growth and growth velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subclinical heart dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Insulin Sensitivity: M-value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24 Hour Mean Fatty Acid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Flow-mediated Brachial Artery Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: State 3 Mitochondrial Oxygen Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-Operative Pain Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve of 3rd generation cephalosporins resistant enterobacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serum Osmolarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in microbial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 24-h Area under the Curve at steady state (AUCt,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Walking Bouts Per Hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Turns Per Hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability in the Turn Rate Per Step (CoV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Maximum Observed Serum Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Area Under Serum Concentration-Time Curve (AUC(0-T) and AUC(INF))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient-rated wrist evaluation (PRWE) questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quadriceps Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Degree of functional limitations in daily life activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Health status in subjects with post-stroke spasticity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Female infertility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Selective loss of episodic odor memory (Poor POEM status)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence of Bothersome Urinary Incontinence at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total Grade of Conjunctival Hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Upper Lid Margin Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Average Corneal Staining Area Grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Increased MMP-2 and -9 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of coronary artery lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of coronary artery lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Electronically monitored medication adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of salivary biomarkers with blood pressure percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Predictive utility of salivary biomarkers for development of metabolic syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 5-HT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Bone Regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of Bone Regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of kidney disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Oxygenation Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary ventilation Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: IMV Need
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of successfully executed prehospital teleconsultations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: BMI Z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sum of skin fold thicknesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: inflammation factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tumor Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: First Occurrence of Any Serious Vascular Event (SVE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: First Occurrence of Any Major Bleed
Endpoint domain: Adverse events/effects
Primary endpoint: number of elderly women with sufficient vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ureteral peristalsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Detection of drug resistant clone with ctDNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Experiencing Regimen-related Toxicity Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Experiencing Graft Failure
Endpoint domain: Mortality/survival
Primary endpoint: Incidence With Nonrelapse Mortality (NRM) by Day 200
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Pathological Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants Experiencing a Flare
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from hospitalization for recurrent VT
Endpoint domain: Mortality/survival
Primary endpoint: Absence of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of images successfully obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean severity of episodes of FLS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Right heart load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Chemotherapy sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics Tmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics AUC-infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse event and safety laboratory assessments
Endpoint domain: Adverse events/effects
Primary endpoint: PTSD Checklist for DSM-5 (PCL-5) Total Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Baby's Weight at Birth in Pounds/Ounces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Gestation Length in Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baby's APGAR Score at Birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Left Ventricular torsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of days until first visit to a comprehensive care center for HIV care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of days until initiation of antiretroviral therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: End systolic and diastolic dimension of the left and right ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: velocity rate of anterior retraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of T-cell malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Corporal temperature of preterm infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temperature of the incubator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of positive test results after prescribed protective measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: frequency of positive test results within the family or other social groups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Failure rate of DropSafe safety pen needle
Endpoint domain: Adverse events/effects
Primary endpoint: Bioavailability of Nexvax2 constituents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Evaluation Inventory-Short Form (TEI-SF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Exercise-Specific Satisfaction Survey (ESSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: subjective surgeon preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in hemodynamic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Antitussive effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bone-specific alkaline phosphatase (U/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tartrate resistant acid phosphatase (U/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of Monohydroxybutenylmercapturic Acid (MHBMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Levels of Total 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-butanol (Total NNAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: leukemia free survival (LFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in the Health Care Providers Pain and Impairment Relationship Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Pain Self-Efficacy Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ORR of HCC patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: occurrence of unacceptable toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Bone mineral density of lumbar spine (L1-L4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clostridium Difficile Infection Occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of Bacterial IV Stopcock Lumen Contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CLDQ-NAFLD
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 36-Item Short Form Survey (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dose-dependent Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with adverse device effects
Endpoint domain: Adverse events/effects
Primary endpoint: CSF osteopontin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systematic inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absolute Change From Baseline in T Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute Change From Baseline in HDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute Change From Baseline in LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Absolute Change From Baseline in Hgb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Absolute Change From Baseline in Hct
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Absolute Change From Baseline in Prostate Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: changes in the secretion of IL-1 beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Degree of Asymptomatic Intracranial Stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of total immune cell numbers in enthesial tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average duration of treatment with ibrutinib
Endpoint domain: Resource use
Primary endpoint: Proportion of patients requiring dose reduction and/or discontinuation of therapy
Endpoint domain: Resource use
Primary endpoint: Dynamics of QoL indicators
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Clinical Global Impression of Severity scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biodistribution of F-Miso PET scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Swing phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stance phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Double support time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation in screening for AIDS clinical trials
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients enrolled in their ideal Medicare Part D plan
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of P.falciparum genotypes identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient adherence to use a walking Platform
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) for Plasma Gepotidacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) for Plasma Gepotidacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in expression of IL-5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Muscle fiber size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall change in muscle belly length of the medial gastrocnemius muscle and the semitendinosus muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Vital Bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Acromegaly Quality of Life (ACROQoL) Global Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Modified Von Korff pain scale for headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Electrophysiology Measure of AH Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Electrophysiology Measure of HV Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Electrophysiology Measure of Right Ventricular Refractory Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to new affective episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech Understanding in Noise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent and Child Perception of Hearing Loss Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: reduction of serum AMH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Salivary oxytocin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free survival at 6-months
Endpoint domain: Mortality/survival